Samuel Hume, Doctor, scientist and Co-founder of Stematic Labs, shared a post by Arndt Vogel, Head of the Center for Personalized Medicine, MHH at Medical University of Hanover, adding:
- “Pancreatic cancers with a KRAS mutation: 90%
- Approved KRAS inhibitors in pancreatic cancer: 0
- KRAS inhibitors in trials for pancreatic cancer: 10
There are lots of results due this year, including (most excitingly) for Daraxonrasib, which has a phase 3 readout.”
Quoting Arndt Vogel‘s post:
“Emerging landscape of KRAS inhibitors in cancer treatment.
Great review. Tsunami of new drugs and oppertunities.”
Title: Emerging landscape of KRAS inhibitors in cancer treatment
Authors: Jakob Riedl, Hiroyuki Matsubara, Reid McNeil, Parasvi Patel, Ferran Fece de la Cruz, Doga Gulhan, Ryan Corcoran
Read the Full Article.
